Satoshi Akagi

Medicine & Life Sciences

1. Pulmonary Arterial Hypertension 100%
2. Epoprostenol 54%
3. Pulmonary Artery 42%
4. Familial Primary Pulmonary Hypertension 37%
5. Pulmonary Hypertension 34%
6. Lung 25%
7. Monocrotaline 24%
8. Smooth Muscle Myocytes 22%
9. 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol 22%
10. Heart Failure 19%
11. Lung Transplantation 15%
12. voglibose 15%
13. Nanoparticles 13%
14. Cardiomegaly 13%
15. Hemodynamics 12%
16. Therapeutics 12%
17. LCZ 696 12%
18. Vascular Resistance 11%
19. Atrial Heart Septal Defects 10%
20. Imatinib Mesylate 10%
21. Receptor for Advanced Glycation End Products 10%
22. Cardiac Myocytes 10%
23. Fibrosis 9%
24. Platelet-Derived Growth Factor 8%
25. Pharmaceutical Preparations 8%
26. Ventricular Heart Septal Defects 8%
27. Myocarditis 8%
28. Drug Delivery Systems 8%
29. Elasticity 8%
30. Hypertension 7%
31. (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid 7%
32. Pulmonary Veno-Occlusive Disease 7%
33. 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol 7%
34. Bosentan 7%
35. Aneurysm 7%
36. Phosphodiesterase 5 Inhibitors 7%
37. Cardiac Catheterization 7%
38. beraprost 7%
39. Pressure 7%
40. Arteriovenous Malformations 6%
41. riociguat 6%
42. Catheter-Related Infections 6%
43. Isoproterenol 6%
44. Sildenafil Citrate 6%
45. Technetium Tc 99m Pyrophosphate 6%
46. Pulmonary Arteriovenous Fistulas 6%
47. Diabetes Mellitus 6%
48. Tomography 6%
49. Amyloidosis, Hereditary, Transthyretin-Related 6%
50. Vildagliptin 5%